Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
NCT00322673
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class
Stopped
Study was terminated due to cardiac toxicities
Conditions
Acute Myeloid Leukemia
AML
Interventions
DRUG:
XL999
Sponsor
Symphony Evolution, Inc.